Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan
Takanori Kanematsu(Matsuyama Red Cross Hospital), Saburo Sone(Io Therapeutics (United States)), Seiji Yano(Kanazawa University Hospital), Yuko Toyoda(Tokushima University), Yasuhiko Nishioka(Tokushima University), Hiroya Tada(Tokushima University), Masahiko Azuma(Tokushima University), Shoji Sakiyakma(Tokushima University), Hisatsugu Goto(Tokushima University), Hideki Tomimoto(Tokushima University), Takashi Haku(Tokushima Prefectural Central Hospital), Katsuhiro Kinoshita(Tokushima University), Kazuya Kondo(Tokushima University), Momoyo Azuma(Tokushima University Hospital), Hiroyasu Bando(Tokushima Prefectural Central Hospital), Masaki Hanibuchi(Tokushima University), Masayuki Sumitomo(Tokushima Prefectural Central Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Jun Kishi(Tokushima University), Koichiro Kenzaki(Tokushima University), Toshiyuki Hirose(Tokushima Hospital), Kazuo Yoneda(Tokushima Prefectural Central Hospital), Satoshi Sakaguchi(Tokushima University Hospital)
Cited by 15
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175